Trending News

Israeli Scientists’ Breakthrough Drug, Kills HIV Virus; Cure for AIDS Approved?

By yasmin reyes | Update Date: Nov 03, 2016 06:37 AM EDT

The Hebrew University in Jerusalem has developed a breakthrough drug that causes HIV virus cells to self-destruct. Israeli scientists are making further tests to ascertain if the new drug really cures AIDS.

The new drug was able to reduce the number of the HIV virus by as much as 97 percent. It was administered in test tubes containing blood samples from patients with AIDS.

The Gamorra drug was developed by Abraham Loyter and Assaf Friedler of the Hebrew University using Peptide as its most active protein. The drug is currently being tested at the Kaplan Medical Center in Rehovot.

The Peptide in the drug works by bringing duplicate copies of the DNA of the virus to an infected cell. The presence of so many copies causes the HIV cells to self-destruct. It has also been discovered that the drug improves certain bodily functions and processes that consequently kills infected cells, according to the report in The Times of Israel.

As of now, HIV treatment is similar to treating a chronic disease by using a cocktail of medications to slow down the infection. Current drugs are able to prolong the life of an HIV/AIDS patient, but not fully eradicating the virus.

The new drug eliminates all HIV cells, preventing these from coming back. As a result, an AIDS patient will no longer have any HIV virus in his body.

The breakthrough drug of the Israelis may be able to accomplish much if the Peptide works the same way when inserted into a live human body as it does with the blood in the test tubes.

For now, the drug manufactured by Zions Pharmaceuticals is still awaiting approval, based on the report by Breibart. The year 2017 is the target date for clinical trials on HIV-infected persons. Only then can it be ascertained that the Israeli scientists have finally found a cure for AIDS.

© 2024 Counsel & Heal All rights reserved. Do not reproduce without permission.

Join the Conversation

Real Time Analytics